Abbott Laboratories Pakistan reports higher quarterly profit for the quarter ended September 30, 2026
Financial ResultThe board approved financial results for the quarter ended September 30, 2026. Net sales, gross profit, operating profit, net profit and EPS were higher than in the same quarter last year. The quarterly report will be transmitted separately through PUCARS.
Key Findings
- Quarterly net sales were Rs. 20,629.742 million, compared with Rs. 19,819.134 million a year earlier.
- Quarterly net profit rose to Rs. 2,543.951 million from Rs. 1,822.546 million; EPS increased to Rs. 25.99 from Rs. 18.62.
- The September 30, 2026 balance sheet reports cash and cash equivalents of Rs. 10,374.526 million, versus Rs. 13,337.551 million at September 30, 2025.
Financial Performance
| Metric | PreviousQuarter ended September 30, 2025 | CurrentQuarter ended September 30, 2026 | Change |
|---|---|---|---|
| Sales-net | PKR 19.82B | PKR 20.63B | +4.1% |
| Gross profit | PKR 6.73B | PKR 7.76B | +15.4% |
| Profit after operating expenses | PKR 3.17B | PKR 4.22B | +32.9% |
| Net profit for the period | PKR 1.82B | PKR 2.54B | +39.6% |
| Basic and diluted earnings per share | 18.62 | 25.99 | +39.6% |
| Finance costs | PKR 17.66M | PKR 16.15M | -8.6% |
| Cash and cash equivalents | PKR 13.34B | PKR 10.37B | -22.2% |
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.


